Home
This site is intended for healthcare professionals
Sign upLog in
MedAll Oncology
MedAll Oncology
Anna Marie Botictic
Musab Mohamed Osman
Amr Shadad
Dr Amol Kotalwar
Noman Ahmed
George Bashour
Rhea Taip
Ibrahim khalid Mohamed Ahemd Salim
Nasrin Akter Jahan
Ghada Abdelrafee
Desilyn Alana
Ahmednur Sheikabdurahman
Alan Gibson
Meuthia Annisa
Shahnawaz Khan
DR USAMA FAROOQ HANJRA
faizan Khan
Anna Marie Botictic
Musab Mohamed Osman
Amr Shadad
Dr Amol Kotalwar
Noman Ahmed
George Bashour
Rhea Taip
Ibrahim khalid Mohamed Ahemd Salim
Nasrin Akter Jahan
Ghada Abdelrafee
Desilyn Alana
Ahmednur Sheikabdurahman
1151 followers
OverviewEvents & videosThreadsResourcesPeopleAbout
Patient Leaflets for Clinical Oncology
1L HER2+ / HR+ MBC: Integration Map
Advanced Prostate Cancer Question Bank
Appraising and Applying Clinical Trial Data in Advanced Prostate Cancer: Key Clinical Summary
Differentiation of emerging endocrine therapies in ER⁺/HER2⁻ mBC based on MoA and clinical role
Emerging Therapies and Multidisciplinary Management in Advanced Prostate Cancer: Key Clinical Summary
HER2+ MBC Updates from San Antonio Breast Cancer Symposium 2025
Key Clinical Summary: BRAF-driven treatment decisions - Biomarker testing in practice
Key Clinical Summary: BRAF-driven treatment decisions - First line personalization and adverse events management
Key Clinical Summary: BRAF-driven treatment decisions - The patient perspective
Key Clinical Summary: Cancer Cachexia Update: Focus on Emerging Therapies
Key Clinical Summary: Cancer Cachexia – The Patient Perspective
Key Clinical Summary: Cancer Cachexia: Early Recognition and Comprehensive Care
Key Clinical Summary: Cancer Cachexia: Multimodal Interventions and Multidisciplinary Management
Key Clinical Summary: Evolution and Rationale for Maintenance De-Escalation in 1L HER2⁺ MBC
Key Clinical Summary: Optimizing Maintenance in HER2+ Metastatic Breast Cancer
Key Clinical Summary: The Role of Endocrine Therapy ± CDK4/6 Inhibitors in HER2+/HR+ MBC 1L Setting
MedAll Education Link
Navigating Treatment Decisions in Metastatic Prostate Cancer: Key Clinical Summary
Optimize post-CDK4/6 sequencing in ER⁺/HER2⁻ mBC based on clinical and molecular resistance patterns
Optimizing Maintenance in HER2+ Metastatic Breast Cancer: A thread
Personalizing Therapy in ER⁺/HER2⁻ Metastatic Breast Cancer via Biomarkers and Evidence-Based Decision-Making
Relapsed/Refractory Multiple Myeloma Question Bank